Quick Answer
InMed Pharmaceuticals Inc. reported Gross Profit of $1.71 million for the year ending 2025.
- InMed Pharmaceuticals Inc. showed an increase of +55.0% in Gross Profit from 2024 to 2025.
- This data is from InMed Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2021: $111.6 thousand | Q1 2022: $182.3 thousand | Q3 2022: -$491.0 thousand | Q4 2022: $131.2 thousand | Q1 2023: $192.5 thousand | Q3 2023: $21.2 thousand | Q4 2023: $324.1 thousand | Q1 2024: $289.5 thousand | Q3 2024: $493.4 thousand | Q4 2024: $460.9 thousand | Q1 2025: $175.6 thousand | Q3 2025: $403.2 thousand | Q4 2025: $184.2 thousand.
- Over the full 4 years of available data (2022 to 2025), InMed Pharmaceuticals Inc.'s Gross Profit has grown by 214.0%.
- Historical annual values: Fiscal year 2025: $1.71 million | Fiscal year 2024: $1.10 million | Fiscal year 2023: $1.40 million | Fiscal year 2022: $543.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: